Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints

Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology


Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 11 days



Related Stories




Related Tags



StackHealth Time Machine





NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.